PMID- 23989190
OWN - NLM
STAT- MEDLINE
DCOM- 20131209
LR  - 20211021
IS  - 1552-5783 (Electronic)
IS  - 0146-0404 (Print)
IS  - 0146-0404 (Linking)
VI  - 54
IP  - 10
DP  - 2013 Oct 9
TI  - BDNF treatment and extended recovery from optic nerve trauma in the cat.
PG  - 6594-604
LID - 10.1167/iovs.13-12683 [doi]
AB  - PURPOSE: We examined the treatment period necessary to restore retinal and visual 
      stability following trauma to the optic nerve. METHODS: Cats received unilateral 
      optic nerve crush and no treatment (NT), treatment of the injured eye with 
      brain-derived neurotrophic factor (BDNF), or treatment of the injured eye 
      combined with treatment of visual cortex for 2 or 4 weeks. After 1-, 2-, 4-, or 
      6-week survival periods, pattern electroretinograms (PERGs) were obtained and 
      retinal ganglion cell (RGC) survival determined. RESULTS: In the peripheral 
      retina, RGC survival for NT, eye only, and eye + cortex animals was 55%, 78%, and 
      92%, respectively, at 1 week, and 31%, 60%, and 93%, respectively, at 2 weeks. 
      PERGs showed a similar pattern of improvement. After 4 weeks, RGC survival was 
      7%, 29%, and 53% in each group, with PERGs in the dual-treated animals similar to 
      the 1- to 2-week animals. For area centralis (AC), the NT, eye only, and eye + 
      cortex animals showed 47%, 78%, and 82% survival, respectively, at 2 weeks, and 
      13%, 54%, and 81% survival, respectively, at 4 weeks. Removing the pumps at 2 
      weeks resulted in ganglion cell survival levels of 76% and 74% in the AC at 4 and 
      6 weeks postcrush, respectively. The PERGs from 2-week treated, but 4- and 6-week 
      survival animals were comparable to those of the 2-week animals. CONCLUSIONS: 
      Treating the entire central visual pathway is important following optic nerve 
      trauma. Long-term preservation of central vision may be achieved with as little 
      as 2 weeks of treatment using this approach.
FAU - Weber, Arthur J
AU  - Weber AJ
AD  - Department of Physiology, Neuroscience Training Program, Michigan State 
      University, East Lansing, Michigan.
FAU - Harman, Christine D
AU  - Harman CD
LA  - eng
GR  - R01 EY011159/EY/NEI NIH HHS/United States
GR  - EY11159/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Research Support, N.I.H., Extramural
DEP - 20131009
PL  - United States
TA  - Invest Ophthalmol Vis Sci
JT  - Investigative ophthalmology & visual science
JID - 7703701
RN  - 0 (Brain-Derived Neurotrophic Factor)
RN  - 0 (Neuroprotective Agents)
SB  - IM
MH  - Animals
MH  - Brain-Derived Neurotrophic Factor/*therapeutic use
MH  - Cats
MH  - Disease Models, Animal
MH  - Electroretinography
MH  - Nerve Crush
MH  - Neuroprotective Agents/*therapeutic use
MH  - Optic Nerve Injuries/*drug therapy/pathology/physiopathology
MH  - Recovery of Function
MH  - Retinal Ganglion Cells/physiology
MH  - Visual Cortex
PMC - PMC3803139
OTO - NOTNLM
OT  - neurotrophins
OT  - optic neuropathy
OT  - retina
EDAT- 2013/08/31 06:00
MHDA- 2013/12/16 06:00
PMCR- 2014/04/01
CRDT- 2013/08/31 06:00
PHST- 2013/08/31 06:00 [entrez]
PHST- 2013/08/31 06:00 [pubmed]
PHST- 2013/12/16 06:00 [medline]
PHST- 2014/04/01 00:00 [pmc-release]
AID - iovs.13-12683 [pii]
AID - 10.1167/iovs.13-12683 [doi]
PST - epublish
SO  - Invest Ophthalmol Vis Sci. 2013 Oct 9;54(10):6594-604. doi: 
      10.1167/iovs.13-12683.